Piccaluga Pier Paolo, Agostinelli Claudio, Righi Simona, Zinzani Pier Luigi, Pileri Stefano A
Haematologica. 2007 Apr;92(4):566-7. doi: 10.3324/haematol.10767.
Peripheral T-cell lymphoma unspecified (PTCL/U) is a rare tumor characterized by poor treatment response and a dismal prognosis. We studied CD52 expression in 97 PTCL/U cases by immunohistochemistry on tissue-microarrays. Furthermore, CD52 gene expression was studied in 28 cases for which RNA was available. We found that CD52 is expressed in approximately 40% of PTCLs/U at the same level as in normal T-lymphocytes. Although other factors may play a role in the in vivo response to alemtuzumab, an anti-CD52 monoclonal antibody, the estimation of CD52 expression may provide a rationale for the selection of patients with a higher probability of treatment response.
外周T细胞淋巴瘤，非特指型（PTCL/U）是一种罕见肿瘤，其特征为治疗反应差且预后不良。我们通过组织芯片免疫组化研究了97例PTCL/U病例中的CD52表达情况。此外，对28例可获取RNA的病例研究了CD52基因表达。我们发现约40%的PTCL/U中CD52的表达水平与正常T淋巴细胞相同。尽管其他因素可能在体内对阿仑单抗（一种抗CD52单克隆抗体）的反应中起作用，但评估CD52表达可为选择治疗反应概率较高的患者提供理论依据。
